Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Castle Biosciences Inc.

< Previous 1 2 3 Next >
Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Third Quarter 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Second Quarter 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.